Saturday 17 October 2026
Export BNR’s income statement to Excel — free account
Burning Rock Biotech Limited Sponsored ADR
BNR Healthcare Diagnostics & Research
Burning Rock Biotech Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $77.2 million, up 9.18% from fiscal 2024. In the quarter to June 2026, revenue fell 4.22%, EPS fell 98.4%, free cash flow grew 46.0% and total debt fell 5.02%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
12.69
2.91
−18.65%
Follow BNR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (13.08%) | (11.17%) | (10.14%) | (19.18%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
5 | 6 | 6 | 6 | |
| (8.81%) | (7.40%) | (6.64%) | (12.79%) | ||
ROIC |
(50.66%) | (37.52%) | (61.14%) | (75.01%) | |
Return on Tangible Assets |
(14.11%) | (11.89%) | (10.59%) | (21.52%) | |
Average Days of Receivables |
126.29 | 116.89 | 114.74 | 127.63 | |
Free Cash Flow per Share |
(0.02) | (0.05) | (1.52) | (0.37) | |
Free Cash Flow |
(2.21) | (5.07) | (16.19) | (4.01) | |
Capital Expenditures |
— | — | (12.13) | — | |
| Other line items | |||||
Cash ROIC |
(1.63%) | (3.52%) | (11.12%) | (2.76%) | |
Accounts Receivable Turnover |
2.83 | 3.25 | 3.42 | 2.98 | |
Accounts Payable Turnover |
5.26 | 5.01 | 3.74 | 4.73 | |
Inventory Turnover |
2.86 | 2.25 | 2.52 | 2.32 | |
Average Days of Payables |
51.47 | 50.35 | 108.82 | 88.33 | |
Days of Inventory on Hand |
97.85 | 151.50 | 129.74 | 140.35 | |
Tax Rate |
0.02 | 0.03 | 0.03 | 0.05 | |
Research and Development Expense of Revenue |
27.03% | 29.86% | 30.86% | 33.96% | |
Selling, General and Administrative Expense of Revenue |
60.42% | 56.06% | 53.98% | 55.22% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 139.20% | 0.00% | |
Interest Coverage |
(1,191.25) | (15.14) | (6.00) | (9.48) | |
Operating CF/Net income |
0.22 | 0.59 | 0.51 | 0.25 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 10.58 | 0.00 | |
Capex/Depreciation |
— | — | (0.26) | — | |
Revenue per Share |
0.68 | 0.71 | 7.26 | 6.85 | |
Operating CF per Share |
(0.02) | (0.05) | (0.38) | (0.37) | |
Capex per Share |
0.00 | 0.00 | (1.14) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.16 | 0.00 |
Columns are period end dates